ATLANTA, April 30, 2013 /PRNewswire/ — Femasys Inc., a medical device developer of women’s healthcare solutions, announced today the U.S. launch of the 510(k) cleared FemCerv™, an innovative endocervical curettage device. FemCerv is designed to collect a complete, non-contaminated tissue sample with minimal patient discomfort. Endocervical curettage has the potential for the detection of high-grade lesions or invasive cancer that may not be detected by other methods. Femasys plans to initially focus on the U.S., where approximately 3.5 million women each year undergo a follow-up screening for cervical cancer.
Commenting on the announcement, Kathy Lee-Sepsick , President & CEO of Femasys Inc., said, “FemCerv serves to improve cancer screening options for women and allow physicians to provide the best care for their patients. As we continue to offer revolutionary new products into the women’s healthcare market, Femasys is driven by the difference we are making in the lives that we touch.”
Limited U.S. market release of FemCerv has been extremely positive. Femasys will provide hands-on demonstrations of the FemCerv Endocervical Sampler at the upcoming American Congress of Obstetricians and Gynecologists’ (ACOG) 61st Annual Clinical Meeting in New Orleans, Louisiana, from May 5-8 at booth number 801.
Along with the CE mark, this 510(k) cleared device allows Femasys to expand commercialization efforts worldwide. The company is actively seeking strategic partners.
Additional product information can be found at www.femcerv.com
